Suitably-controlled sero-surveillance surveys are essential for evaluating Human Papillomavirus (HPV) immunization programmes. A panel of plasma samples from 18 year old females was assembled, the majority being from bivalent vaccinees.
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Abstract
Suitably-controlled sero-surveillance surveys are essential for evaluating Human Papillomavirus (HPV) immunization programmes. A panel of plasma samples from 18 year old females was assembled, the majority being from bivalent vaccinees.
Antibody specificities were evaluated by three independent laboratories and 3 pools were created that displayed either no antibodies to any HPV type tested, intermediate or high antibody levels to HPV16, HPV18, HPV31 and HPV45. These pools will be useful as control reagents for HPV serology.
Main text
The link between persistent infection with high-risk Human Papillomavirus (HPV) and the development of cervical cancer, the second most common cancer in women worldwide, is well established. The development of highly efficacious vaccines against the two most prevalent genotypes, HPV16 and HPV18 (14) , represents one of the most significant advances in human vaccination for many years (13, 16, 20) .
Emerging data from efficacy trials also suggest some degree of cross-protection against non-vaccine types, including HPV31 and HPV45 (1, 16) .
Serologic assays for the evaluation of HPV vaccine responses are currently limited to an ELISA (9), three multiplex assay systems (4, 6, 15) , and a pseudovirus neutralization assay (2) and emerging data suggest that each system has some utility for characterizing HPV vaccine antibody specificity (3, 19) . Protection against vaccine types is thought to be mediated by neutralizing antibodies (18) and while the mechanism of vaccine-induced cross-protection is uncertain, the measurement of antibodies against non-vaccine types (5, 12) may be useful as a potential correlate or surrogate of cross-protection (17) . The only internationally available serologic standard is a WHO International Standard (IS) for HPV16 antibodies, derived from subjects with natural HPV16 infection (7) although a candidate IS for HPV18 antibodies, derived from subjects with HPV18 natural infection, is currently being characterized.
The aim of this study was to create serologic reference reagents for use as quality controls in post-immunization sero-surveillance surveys able to control for responses against vaccine (HPV16 and HPV18) and non-vaccine types (HPV31 and HPV45).
While IS are essential for assigning an international unitage of antibody levels, the daily quality control of serological tests needs to have access to secondary standards that are available in higher amounts than the IS itself. Such secondary standards should preferably be characterized by analysis of antibody level in parallel with the IS, to assign a traceable International Unitage (IU) to them (22) . The reference reagents described in this paper have the high antibody levels that are typical of vaccinated subjects which makes them easier to use as reference standards for laboratories that perform serology mostly on vaccinated subjects and who have antibody levels substantially higher than found in the IS. (21) . Serum is thought to be the ideal sample for HPV neutralization assays due to the potential for heparin to interfere with the assay (2); however, as these plasma samples were collected as citrated plasma packs, this is not expected to be an issue. respectively, although these discrepancies were not significant. Of the eight plasma samples for which no neutralization activity was detected, four of these had serological reactivity against one or more α or β HPV types not included in the neutralization panel: P07 (HPV6, HPV32), P16 (HPV6), P20 (HPV68, HPV76) and
P27 (HPV38).
These data were used to assemble HPV Negative, Intermediate HPV16/18 antibody and High HPV16/18 antibody plasma pools whose specificity was confirmed by Laboratory A in the pseudovirus neutralization assay ( Table 1 and P19) that were negative for neutralizing antibodies against HPV16, HPV18, HPV31 and HPV45 (Figure 1 ) and negative for binding antibodies against all of the α and β HPV types by multiplex serology.
The intermediate HPV16/18 antibody plasma pool (Table 1) comprised two plasmas (P18 and P21) that displayed intermediate levels of neutralizing antibody against HPV16 and HPV18; plasma P18 also displayed some neutralizing antibody activity against HPV31 (Figure 1) . Both plasmas were positive for binding antibodies against HPV16 and HPV18 and, apart from P18 having some reactivity against HPV32 (α1), these samples were negative for binding antibodies against other α and β HPV types tested by multiplex serology. The median HPV16 neutralizing antibody titer for this plasma pool when expressed as International Units (IU) was 187 IU/mL (InterQuartile Range, IQR, 126-211; n=3), consistent with being a low to intermediate vaccine response (7) .
The high HPV16/18 antibody plasma pool ( Table 1) Overall, the results obtained from testing the plasma pools were similar to those expected from the average of the responses for the individual plasma samples.
Antibody titers derived from natural infection are significantly lower than for vaccinees (8) and HPV16, HPV18, HPV31 and HPV45 co-infections, particularly in this age group, are rare (10, 11). Together these data suggest that the plasma samples with high titer antibodies against both HPV16 and HPV18 (including those with reactivity against HPV31 and HPV45) are almost certainly a result of vaccination. Our panel is not perfectly representative of most vaccinees due to the age of vaccination in the catch-up cohort being rather older than the target age for routine immunization. However, the neutralization responses measured using these plasma pools are indistinguishable from the responses seen with sera taken from 13-14 year old vaccinees (5) . Low levels of antibodies generated by vaccination and/or natural infection towards other α and β HPV types, as suggested from multiplex serology, cannot be ruled out.
Surveillance studies are important for estimating the prevalence of an infectious agent in, or for monitoring the impact of a vaccine on, a population or demographic group. With the recent introduction of the HPV vaccines, many countries are conducting post-vaccine surveillance, including sero-epidemiology surveys. These plasma pools will be useful as reference reagents. They are currently available as 250μL aliquots of liquid plasma archived at -80C and can be obtained from the National Institute for Biological Standards and Control.
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